New drug combo may boost survival in advanced hodgkin lymphoma

NCT ID NCT06984146

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This study tests whether a flat 40 mg dose of nivolumab, when added to standard chemotherapy (AVD), can help people with newly diagnosed advanced classic Hodgkin lymphoma live longer without their cancer getting worse. About 54 adults will take part. The goal is to see if this combination improves remission rates and overall survival while keeping side effects manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation

    RECRUITING

    Moscow, Russia

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.